US20230149302A1 - Stable solid fingolimod dosage forms - Google Patents

Stable solid fingolimod dosage forms Download PDF

Info

Publication number
US20230149302A1
US20230149302A1 US18/091,481 US202218091481A US2023149302A1 US 20230149302 A1 US20230149302 A1 US 20230149302A1 US 202218091481 A US202218091481 A US 202218091481A US 2023149302 A1 US2023149302 A1 US 2023149302A1
Authority
US
United States
Prior art keywords
fingolimod
tablet
dosage form
anionic
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US18/091,481
Other languages
English (en)
Inventor
Fangyu Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Handa Neuroscience LLC
Original Assignee
Handa Neuroscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/084,226 external-priority patent/US9925138B2/en
Application filed by Handa Neuroscience LLC filed Critical Handa Neuroscience LLC
Priority to US18/091,481 priority Critical patent/US20230149302A1/en
Publication of US20230149302A1 publication Critical patent/US20230149302A1/en
Priority to US18/243,735 priority patent/US20240050365A1/en
Priority to US18/919,763 priority patent/US20250041213A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the present invention relates to pharmaceutical dosage forms and methods for preparing pharmaceutical dosage forms containing fingolimod and pharmaceutically acceptable salts, conjugates, or complexes thereof, such as the hydrochloride salt.
  • the pharmaceutical dosage forms of the present invention should be stable upon storage. Embodiments of the present invention should rapidly disintegrate or dissolve in the oral cavity of the patient.
  • the present invention also relates to novel fingolimod salts, conjugates or complexes which can be incorporated into pharmaceutical dosage forms.
  • Pharmaceutically active agents are commonly formulated as solid tablets for oral administration due to reasons of stability, economy, simplicity and convenience of dosing. However, many patients cannot or will not accept tablet administration. Infants, children, individuals suffering from certain injuries or illnesses, and many elderly and disabled individuals cannot swallow or chew sufficiently to effectively administer a pharmaceutically active agent by means of a solid tablet. An effective means for oral administration of pharmaceutically active agents to these individuals would be highly beneficial. While liquid formulations can address this need in some cases, the technical complexities of liquid formulations and difficulties in patient compliance and ease of administration make liquid formulations a less than optimal approach. Thus, there is a great need to develop solid oral tablets which can be administered to this patient population.
  • a solid tablet is used to administer a pharmaceutically active agent, the ability of that preparation to rapidly disintegrate upon contact with the oral cavity, such as the tongue, buccal cavity or sublingual area of the mouth, and to deliver a therapeutically effective dose of the drug would be a major advantage. Furthermore, in many circumstances, it is important to have a fast disintegrating tablet so that the pharmaceutically active ingredient is absorbed as rapidly as possible.
  • Fingolimod is a sphingosine-1 phosphate (SIP) receptor agonist, or modulator, with immunosuppressive activity.
  • Fingolimod, in the form of its hydrochloride salt, is also known as 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride, and has the following structure:
  • Fingolimod was approved in 2010 and is currently marketed in the United States under the tradename GILENYA as an immediate release capsule for the treatment of multiple sclerosis.
  • This formulation contains 0.5 mg equivalent of fingolimod base in the form of the hydrochloride salt.
  • the fingolimod compound and methods for its synthesis and use are described U.S. Pat. No. 5,604,229.
  • Fingolimod contains a primary amine and is known to be susceptible to a Maillard reaction in the presence of reducing sugars. Efforts to prevent this degradation reaction and prepare stable formulations of fingolimod are described in U.S. Pat. No. 8,673,918 and U.S. Published Application Nos. 2006/0275357, 2010/0040678, and 2013/0034603. The aforementioned patent and patent publications teach the use of sugar alcohols to prevent the Maillard reaction and suggest that one of the potential fingolimod dosage forms could be tablets designed to rapidly disintegrating in the oral cavity of a patient.
  • the present invention is a stable pharmaceutically acceptable solid oral dosage form comprising fingolimod or a pharmaceutically acceptable salt, conjugate or complex thereof.
  • Embodiments of the present invention include but are not limited to a pharmaceutically acceptable solid dosage form containing fingolimod or a pharmaceutically acceptable salt, conjugate or complex thereof that rapidly dissolves when placed in a patient’s oral cavity.
  • the present invention also includes methods for producing the pharmaceutically acceptable solid oral dosage forms containing fingolimod or a pharmaceutically acceptable salt, conjugate or complex thereof.
  • the pharmaceutically acceptable solid dosage forms of the present invention comprise fingolimod or a pharmaceutically acceptable salt, conjugate or complex thereof and at least one sugar alcohol.
  • the pharmaceutically acceptable solid dosage forms of the present invention comprise fingolimod or a pharmaceutically acceptable salt, conjugate, or complex thereof and a combination of at least one sugar alcohol and a moisture facilitating compound (hereinafter “MFC”).
  • MFC moisture facilitating compound
  • the sugar alcohol may be any commonly known sugar alcohol, preferably a crystalline sugar alcohol that does not easily convert from a crystalline form to an amorphous form (hereinafter “a NCF sugar alcohol”).
  • the MFC is a hygroscopic compound that readily attracts and/or absorbs moisture from the surrounding air or is a sugar alcohol that easily converts to an amorphous form (hereinafter “a CAF sugar alcohol”).
  • a CAF sugar alcohol when present in the solid dosage form is preferably in an amorphous form in the solid dosage form and the NCF sugar alcohol when present in the solid dosage form is preferably in a crystalline form in the solid dosage form.
  • the pharmaceutically acceptable solid dosage forms of the present invention may further comprise conventional pharmaceutically acceptable excipients such as lubricants, fillers, binders, disintegrants, glidants, solubilizing agents, flavoring agents, gas producing agents, pH adjusting agents, antioxidants, chelating agents, or mixtures of the foregoing.
  • conventional pharmaceutically acceptable excipients such as lubricants, fillers, binders, disintegrants, glidants, solubilizing agents, flavoring agents, gas producing agents, pH adjusting agents, antioxidants, chelating agents, or mixtures of the foregoing.
  • the pharmaceutically acceptable solid dosage forms of the present invention may be prepared by any method known in the pharmaceutical arts such wet granulation, slugging and/or dry mixing the fingolimod with the selected excipients and forming the granules, aggregates or mixtures into tablets.
  • the pharmaceutically solid dosage forms of the present invention are in the form of a tablet, pellet, or granule and exhibits a friability of less than 2%, preferably less than 1.5%, and most preferably less than 1.0%.
  • the pharmaceutically acceptable solid dosage forms of the present invention should dissolve in a patient’s oral cavity or in a United States Pharmacopeia (USP) Disintegration test in less than 2.5 minutes, preferably less than 2.0 minutes, and most preferably less than 1.5 minutes.
  • USP United States Pharmacopeia
  • the pharmaceutically acceptable solid dosage forms are a tablet comprising one or more scored, indented or demassed area that allows the tablets to be divided into portions such as half, thirds or quarters which in turn allows a patient to administer a divided dose.
  • the pharmaceutically acceptable solid dosage forms of the present invention can be prepared by dissolving or suspending the fingolimod or a pharmaceutically acceptable salt thereof in a suitable solvent along with at least one or more pharmaceutically acceptable excipients.
  • the fingolimod is dissolved with at least one solubilizing agent, preferably an anionic surfactant.
  • the resulting fingolimod solution or suspension is sprayed onto or mixed with additional pharmaceutically acceptable excipients such as a sugar alcohol to prepare fingolimod granules that may be further processed into a tablet or pellet, or the granules may be packaged into a unit dose for administration to a patient.
  • the pharmaceutically acceptable solid dosage forms of the present invention can be prepared by dry mixing the fingolimod with at least one pharmaceutically acceptable excipient such as a sugar alcohol.
  • the fingolimod is dry mixed with at least one sugar alcohol and at least one antioxidant.
  • the dry mixture is formed into granules with the aid of a granulating solution or suspension which comprises a suitable solvent and optionally at least one additional pharmaceutically acceptable solvent.
  • the resulting granules may be further processed into a tablet or pellet, or the granules may be packaged into a unit dose for administration to a patient.
  • the pharmaceutically acceptable solid dosage forms of the present invention can be prepared by dissolving or suspending the fingolimod or a pharmaceutically acceptable salt thereof in a suitable solvent along with at least a portion of the MFC, preferably a CAF sugar alcohol and optionally one solubilizing agent, to form a drug/MFC liquid composition and drying the resulting drug/MFC liquid composition to create a matrix comprising the fingolimod or pharmaceutically acceptable salt, conjugate or complex thereof and a MFC.
  • the drying can be conducted by any method known in the pharmaceutical arts including but not limited to spray drying, freeze drying (sometimes referred to as lyophilization), vacuum drying or conventional oven drying.
  • a sugar alcohol preferably an NCF sugar alcohol, or a portion thereof, may be added to the drug/MFC liquid composition prior to drying.
  • a sugar alcohol preferably an NCF sugar alcohol, or a portion thereof, may be combined with the drug/MFC liquid composition during the drying process, i.e., as a substrate during the spray drying, or a sugar alcohol or a portion thereof may be combined with the dried matrix comprising the fingolimod or pharmaceutically acceptable salt, conjugate or complex and the MFC.
  • one or more of the additional pharmaceutically acceptable excipient(s) such as fillers, binders, disintegrants, glidants, solubilizing agents, flavoring agents, pH adjusting agents, antioxidants, chelating agents or mixtures of the foregoing may also be added to the drug/sugar alcohol liquid composition prior to drying.
  • the additional pharmaceutically acceptable excipient(s) may also be added during the drying step, such as a substrate during a spray drying and/or added to the dried matrix comprising the fingolimod or pharmaceutically acceptable salt, conjugate or complex and the MFC.
  • the matrix may be further mixed with a lubricant, and formed into a tablet, pellet, or granule.
  • the pharmaceutically acceptable solid dosage forms of the present invention can be prepared by dry mixing the fingolimod with one or more pharmaceutically acceptable excipients and compressing the mixture into a tablet.
  • the fingolimod may be dry mixed with one or more pharmaceutically acceptable excipients, preferably including an antioxidant, and the dry mix, compacted with an appropriate device such as a roller compactor or a tablet press, and the resulting compacted material is milled and sized to create fingolimod aggregates of desired size.
  • the fingolimod aggregates may be mixed with additional pharmaceutically acceptable excipients such as a lubricant and then pressed into a tablet.
  • the pharmaceutically acceptable solid dosage forms of the present invention i.e., tablet, pellet, or granule
  • they may be humidified for a period of time by exposing the dosage form to an environment of at least about 50% to about 100% relative humidity, preferably about 55% to about 95% relative humidity, and most preferably about 60% to about 90% relative humidity.
  • After humidifying the dosage form it is dried until a hardness of about 10 newtons to about 350 newtons, preferably about 15 newtons to about 250 newtons, and most preferably about 20 newtons to about 150 newtons, is obtained.
  • the period of time for the humidifying step is about 15 minutes to about 40 hours, preferably about 1 hour to about 24 hours, and mostly preferably about 1 hour to about 12 hours.
  • the time period will vary depending upon the relative humidity and temperature of the humidifying step.
  • the period of time for the drying step can vary from about 0.5 hours to about 40 hours, depending upon the temperature and relative humidity of the drying apparatus.
  • This embodiment of the present invention allows the resulting tablets, pellets, or granules to be stored in bulk containers such as polyethylene bags and/or drums for a period of time without significant degradation or breaking. After bulk storage, the solid dosage form may be packaged in bottles or conventional blister packs without significant breaking or destruction.
  • the dosage form should be held in the patient’s mouth or buccal cavity until it dissolves.
  • the patient may swallow the remnants of the dissolved dosage form.
  • T max time to maximum fingolimod concentration
  • C max/dose dose adjusted maximum fingolimod concentration
  • a further embodiment of the present invention is a liquid composition
  • a liquid composition comprising the fingolimod or pharmaceutically acceptable salt, conjugate or complex thereof, and pharmaceutically acceptable excipients such as a MFC, a sugar alcohol, preferably an NCF sugar alcohol, a solubilizing agent or combinations thereof.
  • the liquid composition is filled into individual molds and the liquid removed by freeze drying to create a solid dosage form for oral administration or freeze dried particles that may be incorporated into a solid dosage form for oral administration.
  • a still further embodiment of the present invention is a liquid composition
  • a liquid composition comprising the fingolimod or pharmaceutically acceptable salt, conjugate or complex thereof, and pharmaceutically acceptable excipients such as the MFC, a sugar alcohol, preferably an NCF sugar alcohol, a solubilizing agent or combinations thereof.
  • the liquid composition is filled into individual molds and the liquid removed by vacuum drying to create a solid dosage form for oral administration or vacuum dried particles that may be incorporated into a solid dosage form for oral administration.
  • Another embodiment of the present invention is a fingolimod salt, conjugate or complex formed by reacting fingolimod with an anionic C 10 -C 30 carboxylic acid, an anionic C 10 -C 30 alcohol, an anionic sulfate, an anionic sulfite or a mixture thereof and solid dosage forms containing the fingolimod salt, conjugate or complex formed by reacting fingolimod with an anionic C 10 -C 30 carboxylic acid, an anionic C 10 -C 30 alcohol, an anionic sulfate, an anionic sulfite or mixture thereof.
  • the term “rapidly disintegrates in a patient’s oral cavity” is intended to refer to a solid dosage form comprising a therapeutically effective amount of fingolimod or pharmaceutically acceptable salt, conjugate or complex thereof that dissolves or disintegrates in a test subject’s oral cavity in less than 2.5 minutes, preferably less than 2.0 minutes and most preferably less than 1.5 minutes.
  • the solid dosage form should dissolve or disintegrate between about 5 seconds and about 60 seconds, preferably between about 7 seconds and about 45 seconds, and most preferably between about 10 seconds to about 30 seconds when placed in a patient’s oral cavity such as on or under the tongue or between the test subject’s cheek and gum.
  • the solid dosage form When measuring the amount of time needed for the solid dosage form to completely disintegrate or dissolve in a test subject’s mouth, the solid dosage form is placed on the test subject’s tongue; a chronometer, such as a stop watch, is started as soon as the solid dosage form contacts the tongue.
  • the test subject is instructed that the tablet may be gently moved around the oral cavity without biting, chewing, or sucking on the solid dosage from.
  • the test subject is instructed to immediately stop the chronometer after the last noticeable particle is disintegrated. This test is repeated with the same subject at least three times and the times are averaged.
  • rapidly disintegrates is intended to refer a solid dosage form comprising a therapeutically effective amount of fingolimod or pharmaceutically acceptable salt, conjugate or complex thereof that disintegrates when tested in accordance with the USP procedure and apparatus described in ⁇ 701> Disintegration.
  • the time to disintegrate should be 2.5 minutes or less, preferably 2.0 minutes or less, and more preferably 1.5 minutes or less.
  • the term “friability” refers to a physical strength measurement of a solid dosage form such as a tablet, and is defined as the ability of the solid dosage form to resist abrasion and attrition. It is typically measured by turning tablets in a rotating vessel and determining weight loss. These rotating devices are called “friabilators.” The friabilator provides frictional abrasion to the sample and is used to measure the resistance to abrasion or attrition of samples. The loss of weight is measured after a fixed number of revolutions of a drum rotating at a controlled rate.
  • a friabilator apparatus typically uses a 285 mm drum of transparent synthetic polymer with polished internal surfaces. One side of the drum is removable. The samples are tumbled at each turn of the drum by a curved projection that extends from the middle of the drum to the outer wall. The drum is attached to the horizontal axis of a device that rotates at about 25 rpm to about 30 rpm. Thus, at each turn, the samples roll or slide and fall onto the drum wall or onto each other.
  • the standard USP protocol described in section ⁇ 1216> for measuring friability is used. Briefly, the predetermined number of samples are placed in a friabilator that is a 285 mm drum, about 39 mm in depth, of transparent synthetic polymer. The samples are “tumbled” at each turn of the drum by a curved projection that extends from the middle of the drum. The drum is rotated for about four minutes at about 25 rpm, resulting in a total of 100 rotations. A minimum of about 20 samples are used in any test, unless the samples weigh over 650 mg, in which case only 10 samples are used. After the allotted time, the samples are removed from the friabilator, and, with the aid of air pressure or a brush, adhering particles and dust are removed, and the remaining samples are accurately weighed and the percent loss of weight is calculated.
  • the term “hardness” refers to the physical strength measurement of the solid dosage form such as a tablet.
  • the resistance of a solid dosage form to chipping, abrasion, or breakage under conditions of storage, transportation, and handling before usage depends on its hardness, or “crushing strength.”
  • the “crushing” or “tensile” strength of a solid dosage form is defined as the force required to break a solid dosage form by compression in the radial direction. It is typically measured using one of the many commonly available tablet hardness testers. For example, “Stokes” and “Monsanto” hardness testers measure the force required to break the tablet when the force generated by a coil spring is applied diametrically to the tablet.
  • a “Strong-Cobb” hardness tester also measures the diametrically applied force required to break a tablet, the force applied by an air pump forcing a plunger against the tablet placed on an anvil.
  • Electrically operated hardness testers such as the Schleuniger apparatus (also known as a “Heberlein”) can be used.
  • normal storage conditions refers to storage at room temperature, approximately 25° C. and approximately 60% relative humidity for at least three months, preferably at least six months, and most preferably at least one year.
  • the solid dosage form in accordance with the present invention should be stored in pharmaceutically acceptable containers such as glass bottles, plastic bottles, metal foil pouch, or blister packaging with or without a desiccant.
  • accelerated storage conditions refers to storage at approximately 40° C. and approximately 75% relative humidity for at least two weeks or longer, one month or longer, two months or longer, three months or longer, four months or longer, five months or longer, or six months or longer.
  • the solid dosage form in accordance with the present invention should be stored in pharmaceutically acceptable containers such as glass bottles, plastic bottles, metal foil pouch, or blister packaging with or without a desiccant.
  • amorphous indicates that the material, more particularly, a sugar alcohol in the solid dosage form lacks a defined crystal lattice structure. Whether the material is in an amorphous state can be determined by any of the known analytical techniques. One way used to determine if the sugar alcohol is in an amorphous state is to conduct an x-ray powder diffraction test.
  • the term “substantially” as used to describe, for example, the amount of amorphous sugar alcohol present in a dried matrix of the fingolimod and CAF sugar alcohol means at least 5% or greater, 10% or greater, 15% or greater, 20% or greater, 25% or greater, 30% or greater, 35% or greater, 40% or greater, 45% or greater, 50% or greater, 55% or greater, 60% or greater, 65% or greater, 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, or 95% or greater of the CAF sugar alcohol is present in an amorphous form.
  • MFC moisture facilitating compounds
  • MFCs include CAF sugar alcohols as described in detail below and pharmaceutically acceptable excipients, preferably solid water soluble excipients, that absorb at least 10 wt%, preferably 15 wt% and most preferably 20 wt% of water based on the total dry weight of the excipient when the excipient is placed in an open container and stored at 25° C. and 75% relative humidity, preferably at 25° C.
  • MFC materials include but are not limited to citric acid, povidone, hydroxyethyl cellulose, and hydroxypropyl cellulose.
  • references to fingolimod include fingolimod in its free base form, or as a pharmaceutically acceptable salt, conjugate, complex, solvate or hydrate of the free base or salt forms, or derivatives thereof.
  • fingolimod is in the form of a pharmaceutically acceptable acid addition salt, and more preferably, fingolimod is in the form of its hydrochloride salt.
  • the fingolimod is a salt, conjugate or complex formed by reacting fingolimod, preferably a fingolimod anionic salt such as fingolimod HCl with an anionic C 10 -C 30 carboxylic acid, an anionic C 10 -C 30 alcohol, an anionic sulfate, an anionic sulfite or mixture thereof.
  • the fingolimod is fingolimod HCl in crystalline form, preferably one of the crystalline forms described in U.S. Pat. No. 8,530,522 which is incorporated herein by reference.
  • One particular crystalline form is a hydrate crystal having a water content from about 5.2 to about 10.6 and exhibiting an X-ray powder diffraction pattern with peaks at about 2.9, about 8.6, about 17.2, about 24.4, about 25.9, about 28.2 and about 30.6.
  • the fingolimod HCl may be the previously described hydrate crystal or it may be fingolimod HC1 Form I described in U.S. Pat. No.
  • the fingolimod HCl in the final dosage forms of the present invention may comprise one or more of the afore-described crystal forms or it may also comprise an amorphous form.
  • the particular form, i.e., crystal, amorphous or mixture thereof, of the fingolimod HCl in the final dosage form will depend upon the manufacturing method employed to prepare the dosage form and the storage conditions.
  • the fingolimod HCl employed in the preparation of the dosage forms of the present invention can have a range of particle sizes.
  • the fingolimod should be micronized and exhibit a mean particle size (d50) of less than 50 microns, preferably less than 35 microns and most preferably less than 20 microns.
  • the mean particle size may be determined by any method commonly employed in the pharmaceutical arts, some of which are described in Remington, The Science and Practice of Pharmacy 21 st ed. (2005) pp. 706-711 which is incorporated herein by reference.
  • the fingolimod comprises a fingolimod salt, conjugate or complex formed by reacting fingolimod with an anionic C 10 -C 30 carboxylic acid, an anionic C 10 -C 30 alcohol, an anionic sulfate, an anionic sulfite or mixture thereof.
  • the fingolimod comprises a mixture of fingolimod HCl and a fingolimod salt, conjugate or complex formed by reacting fingolimod with an anionic C 10 -C 30 carboxylic acid, an anionic C 10 -C 30 alcohol, an anionic sulfate, an anionic sulfite or mixture thereof.
  • the phrase “pharmaceutically acceptable salt” refers to any salt of fingolimod which retains the biological effectiveness of fingolimod.
  • pharmaceutically acceptable salts include, but are not limited to, acetates, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates,
  • methane-sulfonate or mesylate propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.
  • propanesulfonates propanesulfonates
  • naphthalene-1-sulfonates propanesulfonates
  • naphthalene-2-sulfonates propanesulfonates
  • naphthalene-2-sulfonates propanesulfonates
  • naphthalene-2-sulfonates propanesulfonates
  • mandelates Several of the officially approved salts are listed in Remington, The Science and Practice of Pharmacy 21 st ed. (2005) .
  • the pharmaceutically acceptable solid dosage forms of the present invention should comprise a therapeutically effective amount of fingolimod or a pharmaceutically acceptable salt, conjugate or complex thereof.
  • the therapeutically effective amount can be easily determined from a review of the available literature and can range from about 0.1 mg to about 50 mg, preferably about 0.15 mg to about 25 mg, and most preferably about 0.2 mg to about 5 mg.
  • the solid dosage forms of the present invention may comprise one or more sugar alcohols. If more than one sugar alcohol is employed, it is preferred that one of the sugar alcohols is a sugar alcohol that easily converts from a crystalline form to an amorphous form, i.e., a CAF sugar alcohol, and the other sugar alcohol is a sugar alcohol that does not easily convert from a crystalline form to an amorphous form, i.e., a NCF sugar alcohol.
  • sugar alcohols examples include arabitol, mannitol, sorbitol, dextrose, dextrin, sucrose, maltose, xylitol, maltitol, lactitol, erythritol, isomalt and mixtures thereof. It is believed that sugar alcohols that may easily convert from a crystalline form to an amorphous form, i.e., CAF sugar alcohols, exhibit a glass transition temperature of about 15° C. or higher after being dried to a constant weight, preferably a glass transition temperature of about 20° C. or higher after being dried to a constant weight, and most preferably a glass transition temperature of about 25° C.
  • sugar alcohols that may easily convert from a crystalline form to an amorphous form include maltitol, lactitol, erythritol, and isomalt. Lactitol is a preferred CAF sugar alcohol.
  • sugar alcohols that do not easily convert from a crystalline form to an amorphous form i.e., NCF sugar alcohols exhibit a glass transition temperature of about 10° C. or lower after being dried to a constant weight, preferably a glass transition temperature of about 5° C. or lower after being dried to a constant weight, and most preferably a glass transition temperature of about 0° C. or lower after being dried to a constant weight.
  • NCF sugar alcohols include mannitol, sorbitol, xylitol, sucrose, and maltose. Mannitol, xylitol, and sucrose are preferred NCF sugar alcohols.
  • the solid dosage forms comprise the fingolimod and pharmaceutically acceptable salts, conjugates and complexes thereof, one or more NCF sugar alcohols as previously described and a MFC excipient.
  • the solid dosage forms of the present invention may comprise about 10 wt% to about 99 wt% of one or more sugar alcohols, preferably about 15 wt% to about 97 wt%, and most preferably about 20 wt% to about 95 wt%.
  • the amount of MFC preferably CAF sugar alcohol, may comprise about 0.5 wt% to about 70 wt% of the total weight of the solid dosage form, preferably about 1 wt% to about 50 wt% of the total weight of the solid dosage form, and most preferably about 5 wt% to about 25 wt% of the total weight of the solid dosage form.
  • the ratio of CAF sugar alcohols to NCF sugar alcohols present in the solid dosage forms of the invention range from about 1(CAF):1(NCF) to about 1(CAF):20(NCF), preferably about 1(CAF):1(NCF) to about 1(CAF):15(NCF), and most preferably about 1(CAF):1(NCF) to about 1(CAF):10(NCF).
  • the pharmaceutically acceptable solid dosage form of the present invention may further comprise conventional pharmaceutically acceptable excipients such as lubricants, fillers, binders, disintegrants, glidants, solubilizing agents, flavoring agents, gas producing agents, pH adjusting agents, antioxidants or mixtures of the foregoing.
  • excipients such as lubricants, fillers, binders, disintegrants, glidants, solubilizing agents, flavoring agents, gas producing agents, pH adjusting agents, antioxidants or mixtures of the foregoing.
  • the amount of these excipients present in the solid dosage forms will vary depending upon the specific and desired properties of the solid dosage form. Ranges and amounts of these excipients are known and reported in the literature.
  • lubricants examples include magnesium stearate, sodium stearyl fumarate, stearic acid, glyceryl behenate, polyethylene glycols (preferably wherein the polyethylene glycol has a molecular weight of 6000 or more), polyoxyethylene stearate, magnesium lauryl sulfate, sodium oleate, and mixtures thereof.
  • the lubricants may be present in an amount ranging from about 0.1 wt% to about 10 wt% based on the total weight of the dosage form, preferably about 0.2 wt% to about 7 wt%, and most preferably about 0.5 wt% to about 5 wt%.
  • fillers examples include dibasic calcium phosphate, microcrystalline cellulose, calcium carbonate, magnesium carbonate, calcium sulfate, powdered cellulose, silicified microcrystalline cellulose, magnesium carbonate, magnesium oxide, starch, and mixtures thereof.
  • binders examples include acacia, povidone, hypromellose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyethylene oxide, polymethacrylates, methyl cellulose, ethyl cellulose, pregelatinized starch, gelatin, tragacanth, zein, or mixtures thereof.
  • the binder is selected from povidone, hypromellose, hydroxypropyl cellulose, hydroxyethyl cellulose, polymethacrylates, methyl cellulose, gelatin and ethyl cellulose, or mixtures thereof.
  • binders include water soluble binders such as povidone, hypromellose, hydroxypropyl cellulose, gelatin and mixtures thereof. If the binder is a polymeric binder, it is preferred that the binder have a low molecular weight and/or exhibit a viscosity of less than 200 mPa s, preferably less than 100 mPa s, and most preferably less than 50 mPa s when tested at a concentration of 2% (w/v) aqueous preparation at 20° C.
  • Binders impart cohesiveness to the solid dosage form and ensure strength of the solid dosage form, especially a tablet after compression.
  • the use of water soluble binders are also important in the embodiments of the present invention that include a humidification step, because it is believed that the water soluble binder will swell upon absorption of the water, allowing more thorough hydration of the other components of the formulation and deeper penetration of the water into the solid dosage form.
  • These water soluble binders may also functions as an MFC.
  • a non-saccharide, water soluble polymeric binder may also act as a disintegrant, contributing to the rapid disintegration properties of the solid dosage form.
  • the non-saccharide, water soluble polymeric binder also contributes to and enhances the “smooth feeling” of the solid dosage form when it dissolves in the patient’s oral cavity.
  • Povidone is an example of a preferred non-saccharide, water-soluble, polymeric binder that may be used in the present invention.
  • Povidone can be obtained from a variety of commercial sources, under tradenames such as KOLLIDON® or PLASDONE®.
  • Povidone is commercially available in a variety of “K-values” which describe the approximate molecular weights. Although any of the commercially available K grades can be used in the present invention, those with a K value of 30 or less are preferred.
  • the non-saccharide, water soluble, polymeric binder can be derivatives of povidone such as a copolymer of N-vinyl pyrrolidone and vinyl acetate (also known as copovidone), 3-methyl N-vinylpyrrolidone, N-vinyl amide pyrrolidone, and the like or mixtures thereof.
  • povidone such as a copolymer of N-vinyl pyrrolidone and vinyl acetate (also known as copovidone), 3-methyl N-vinylpyrrolidone, N-vinyl amide pyrrolidone, and the like or mixtures thereof.
  • Another preferred binder that may be used in the present invention is a low substituted hydroxypropyl cellulose which exhibits a low viscosity when dissolved in water and has no less than 5% and no more than 16% hydroxypropoxy groups.
  • a more detailed description of some of the low substituted hydroxypropyl celluloses can be found in U.S. Pat. No. 7,399,485 which is incorporated herein by reference.
  • Still another preferred binder that may be used in the present invention is gelatin, such as that described in U.S. Pat. Nos. 4,305,502 and 4,371,516 which are incorporated herein by reference.
  • disintegrants examples include croscarmellose sodium, starch, crospovidone, sodium starch glycolate, alginic acid, calcium carboxymethylcellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, powdered cellulose, chitosan, guar gum, magnesium aluminum silicate, methylcellulose, sodium alginate, and mixtures thereof.
  • glidants examples include colloidal silicon dioxide, corn starch, talc and mixtures thereof.
  • solubilizing agents may be employed in the dosage forms of the present invention.
  • the solubilizing agent will aid in dissolving the fingolimod following administration of the dosage form to the patient.
  • solubilizing agents include but are not limited to cyclodextrins, surfactants (sometimes referred to as wetting agents) and mixtures thereof.
  • Cyclodextrins are cyclic oligosaccharides, consisting of alpha-1,4-linked alpha-D-glucopyranose units, with a lipophilic central cavity and hydrophilic outer surface.
  • cyclodextrins form inclusion complexes with drugs such as fingolimod, through a process in which the water molecules located in the central cavity are replaced by all or part of the drug molecule.
  • the cyclodextrin may be an alpha, beta, or gamma type cyclodextrin, alpha, beta, or gamma type cyclodextrin derivatives or a combination thereof.
  • the cyclodextrin derivatives include but are not limited to alkylated cyclodextrins, hydroxyalkyl cyclodextrins, sulfoalkylether cyclodextrins and branched cyclodextrins such a glucosyl- and maltosyl- cyclodextrins.
  • alkylated cyclodextrins include methyl-, ethyl-, propyl-, butyl-, and pentyl- cyclodextrins.
  • hydroxyalkyl cyclodextrins examples include hydroxylethyl-, hydroxypropyl-, hydroxylbutyl-and hydroxypentyl- cyclodextrin.
  • Other possible cyclodextrins that may be used in the present invention can be found in WO 2008/015695 which is incorporated herein by reference.
  • the cyclodextrin may be present in the dosage forms of the present invention in an amount from about 0.1 wt% to about 30 wt% based upon the total weight of the dosage form, preferably about 0.5 wt% to about 20 wt%, and most preferably about 1 wt% to about 15 wt%.
  • the surfactant employed in the present invention may be a non-ionic surfactant, an ionic surfactant or a combination thereof.
  • non-ionic surfactants include polyethoxylated castor oil, a polyoxyethylene alkyl ester, a polyglycolyzed glyceride, a sorbitan fatty acid ester, a glycerin fatty acid ester, a fatty acid polyglyceride, a fatty acid alcohol polyglycol ether, acetylene glycol, acetylene alcohol, an oxyalkylene block polymer, a polyoxyethylene alkyl ether, a polyoxyethylene alkylaryl ether, a polyoxyethylene styrylaryl ether, a polyoxyethylene glycol alkyl ether, a polyoxyethylene fatty acid ester, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene glycerin fatty acid ester, a polyoxyethylene hydrogenated
  • the non-ionic surfactants may comprise fatty alcohol acid or amide ethoxylates, monoglyceride ethoxylates, sorbitan ester ethoxylates alkyl polyglycosides, mixtures thereof, and the like.
  • Certain non-ionic surfactants include polyoxyethylene derivatives of polyol esters, such as Polysorbate 20 (TWEEN 20®), Polysorbate 40 (TWEEN 40®) Polysorbate 60 (TWEEN 60®), and Polysorbate 80 (TWEEN 80®).
  • the non-ionic surfactant may also comprise d-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS), nonoxinols, poloxamers, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, tyloxapol, and mixtures of the foregoing.
  • TPGS d-alpha tocopheryl polyethylene glycol 1000 succinate
  • ionic surfactants include, but are not limited to, carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, phosphates, quaternary ammonium salts, and ethoxylated amines.
  • carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulf
  • an anionic surfactant such as aluminum monostearate, calcium stearate, sulfated castor oil, sodium cetostearyl sulfate, sodium lauryl sulfate, sodium oleate, potassium oleate, zinc oleate, sodium stearate, sodium tetradecyl sulfate and mixtures therefore.
  • the more preferred anionic surfactants are water soluble and may for a complex or derivative of fingolimod when dissolved in an aqueous solution containing a dissolved fingolimod salt.
  • An example of a preferred anionic surfactant is sodium lauryl sulfate.
  • the surfactant may be present in the dosage forms of the present invention in an amount from about 0.01 wt% to about 10 wt% based upon the total weight of the dosage form, preferably from about 0.1 wt% to about 7 wt%, and most preferably from about 0.5 wt% to about 5 wt%.
  • the molar ratio of anionic surfactant to fingolimod should range from about 0.5 moles of anionic surfactant to about 3 moles of anionic surfactant for each mole of fingolimod present in the dosage form, preferably about 0.75 moles of anionic surfactant to about 2 moles of anionic surfactant for each mole of fingolimod present in the dosage form and most preferably about 0.85 moles of anionic surfactant to about 1.5 moles of anionic surfactant for each mole of fingolimod present in the dosage form.
  • flavoring agents examples include artificial sweeteners such as aspartame, saccharin, dipotassium glycyrrhizinate, stevia, thaumatin, and flavorants such as citric acid, peppermint oil, wintergreen oil, menthol, lemon, lime, orange, grape, cherry, and vanilla extract. Additional taste enhancing agents are described in U.S. Pat. No. 6,027,746 which is incorporated herein by reference.
  • gas producing agents sometimes referred to as effervescent agents
  • gas producing agent typically comprises an acid source and a source of carbon dioxide.
  • the acid source can be any of the pharmaceutically acceptable acids discussed below.
  • the carbon dioxide source includes, but is not limited to, carbonate and bicarbonate salts, such as sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, magnesium carbonate and mixtures thereof.
  • pH adjusting agents examples include pharmaceutically acceptable acids or bases which may be present to adjust the pH of intermediate compositions leading up to the final solid dosage form and to adjust the pH of the drug environment of final solid dosage form to a desired or optimum pH range.
  • pharmaceutically acceptable acids include, but are not limited to, acetic acid, citric acid, fumaric acid, hydrochloric acid, malic acid, nitric acid, phosphoric acid, propionic acid, sulfuric acid, tartaric acid, and mixtures thereof.
  • pharmaceutically acceptable bases examples include but are not limited to ammonia, ammonium carbonate, diethanolamine, potassium hydroxide, sodium bicarbonate, sodium carbonate, sodium hydroxide, trolamine, and mixtures thereof.
  • antioxidants examples include ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, potassium metabisulfate, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfate, sodium sulfate, sodium thiosulfate, sodium dioxide, tocopherol, and mixtures thereof.
  • the antioxidant may be present in the dosage forms of the present invention in an amount from about 0.01 wt% to about 20 wt% based upon the total weight of the dosage form, preferably from about 0.1 wt% to about 10 wt%, and most preferably from about 0.5 wt% to about 5 wt%.
  • chelating agent means a molecule containing two or more electron donor atoms that can form coordinate bonds to a single metal ion.
  • chelating agent is understood to include the chelating agent as well as pharmaceutically acceptable salts thereof.
  • chelating agent includes citric acid as well as its salt forms.
  • chelating agents examples include polyphosphates (e.g., sodium tripolyphosphate, hexametaphosphoric acid, sodium acid pyrophosphate, sodium pyrophosphate, tetra sodium pyrophosphate, sodium hexametaphosphate, sodium metaphosphate); aminocarboxylic acids (e.g., ethylenediaminetetraacetic acid (EDTA), 1,2-bis(2-amino-phenoxy)ethane-N,N,N′N′-tetraacetic acid (EGTA), ethylenebis(oxyethylenenitrilo)tetraacetic acid (BAPTA), N-(hydroxyethyl)-ethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA), N-dihydroxyethylglycine (2-HxG), ethylenebis(hydroxyphenyl-glycine) (EHPG), glutamic acid, aspartic acid, glycine
  • polyphosphates e
  • the amount of chelating agent present in the oral dosage form of the present invention will depend on the particular chelating agent or agents (i.e. mixtures of chelating agents) selected. Generally, the amount will range from about 0.5 wt% to about 15 wt% based upon the total weight of the dosage form, preferably from about 0.75 wt% to about 10 wt%, and most preferably from about 1 wt% to about 5 wt%.
  • the solid dosage form of the present invention may be prepared by any method commonly known in the pharmaceutical arts such as wet granulation, slugging and/or dry mixing the fingolimod with the selected excipients and forming the granules, aggregates or mixtures into tablets. Because the oral doses of fingolimod are 5 mg or less, typically in the range of about 0.25 mg to about 1.0 mg, preparing a solid dosage form such as a tablet with a uniform and consistent distribution of fingolimod, i.e., content uniformity, can be difficult.
  • the dosage forms of the present invention exhibit a consistent distribution of fingolimod throughout the dosage form and more importantly, exhibit a consistent distribution of fingolimod throughout the composition blend that is used to fill the tablet dies prior to pressing the composition blend into the tablets.
  • This consistent distribution in the composition blend means that samples taken from the same composition blend will not deviate by more than 5%, preferably will not deviate by more than 3%, and most preferably will not deviate by more than 2% in the amount of fingolimod.
  • the content of the fingolimod in the tablet should be about 90% to about 110% of the theoretical amount of the tablet and subsections or divisible portions of the tablet should also contain about 90% to about 110%, preferably about 93% to about 107%, and most preferably about 95% to about 105% of the theoretical amount of the subsection of tablet.
  • a tablet prepared in accordance with the present invention contains a target or theoretical amount of 1 mg of fingolimod
  • acceptable samples of the tablet may contain about 0.9 mg to about 1.1 mg. If the 1 mg tablet is divided in half, each half should contain a target or theoretical amount of 0.5 mg of fingolimod, acceptable samples of the halved tablet may contain about 0.45 mg to about 0.55 mg of fingolimod.
  • the dosage form of the present invention is a tablet, it may comprise a score, indentation or demassed region that will allow the tablet to be divided into subsections or portions, thereby allowing the patient to administer divided or subdoses.
  • the tablet of the present invention contains a target or theoretical amount of 1 mg of fingolimod
  • the tablet may be divided into two approximately equal halves to allow the patient to administer a single 0.5 mg dose as may be instructed by a physician.
  • a 0.5 mg tablet could be divided into two 0.25 mg halves.
  • the accurate division is enabled by breaking the tablet along a predetermined scored, indented or demassed region of the tablet.
  • the predetermined scored, indented or demassed region may be on one or more surfaces of the tablet.
  • the predetermined score, indentation or demassed region may be on the top, bottom, sides, top and bottom, or top, bottom and sides of the tablet.
  • the score, indentation or demassed region may be formed into the tablet during the compression step by employing a die shape that creates the score, indentation or demassed region.
  • the score, indentation or demassed region may also be formed after the tablet has been formed such as by the use of a laser to remove a portion of the tablet material.
  • the solid dosage form of the present invention can be prepared by dissolving or suspending the fingolimod or a pharmaceutically acceptable salt thereof, such as the HC1 salt, in a suitable solvent such as water, an organic solvent such as C 1 -C 6 branched or straight chain alcohols, ethers, esters or ketones or mixtures thereof along with additional pharmaceutical excipients such as binders, solubilizing agents, antioxidants, chelating agents and mixtures thereof and spraying the resulting fingolimod solution onto a substrate comprising at least one pharmaceutical acceptable excipient such as a sugar alcohol, filler or mixture thereof to create fingolimod granules.
  • the fingolimod granules may be dried, and sized if necessary.
  • the dried and sized fingolimod granules can be blended with additional pharmaceutical excipients such as a lubricant and compressed into a tablet.
  • the solid dosage form of the present invention is prepared by dissolving the fingolimod or a pharmaceutically acceptable salt thereof, such as the HC1 salt, in a suitable solvent such as water, an organic solvent such as C 1 -C 6 branched or straight chain alcohols, ethers, esters or ketones or mixtures thereof along with at least one solubilizing agent and additional pharmaceutical excipients such as MFCs, fillers (including sugar alcohols), binders, antioxidants, chelating agents and mixtures thereof and spraying the resulting fingolimod solution onto a substrate comprising at least one pharmaceutical acceptable excipient such as an MFC, a sugar alcohol, filler or mixture thereof to create fingolimod granules.
  • a suitable solvent such as water, an organic solvent such as C 1 -C 6 branched or straight chain alcohols, ethers, esters or ketones or mixtures thereof along with at least one solubilizing agent and additional pharmaceutical excipients such as MFCs, fillers (including sugar alcohols),
  • the fingolimod granules may be dried, and sized if necessary.
  • the dried and sized fingolimod granules can be blended with additional pharmaceutical excipients such as a lubricant and compressed into a tablet.
  • the solubilizing agent employed in this method is a cyclodextrin and should be used in an amount to fully complex the fingolimod.
  • the weight ratio of fingolimod to cyclodextrin should be at least about 1:5 to about 1:40 or higher, preferably at least about 1:7.5 to about 1:30, most preferably at least about 1:10 to about 1:20.
  • the solubilizing agent employed in this method is a surfactant, preferably an ionic surfactant, and most preferably an anionic surfactant. If an ionic surfactant is employed it is should be present in a weight ratio of fingolimod to ionic surfactant of at least about 1:0.5 to about 1:10 or higher, preferably of at least about 1:0.75 to about 1:8 and most preferably at least about 1:1 to about 1:5.
  • the anionic solubilizing agent employed in this embodiment may form a salt, conjugate, complex or co-precipitate with the fingolimod during the manufacturing process, i.e., during preparation of the granulating liquid or during the spray drying step.
  • molar ratio of anionic surfactant to fingolimod should range from about 0.5 moles of anionic surfactant to about 3 moles of anionic surfactant for each mole of fingolimod present in the dosage form, preferably about 0.75 moles of anionic surfactant to about 2 moles of anionic surfactant for each mole of fingolimod present in the dosage form and most preferably about 0.85 moles of anionic surfactant to about 1.5 moles of anionic surfactant for each mole of fingolimod present in the dosage form.
  • the solid dosage form of the present invention can be prepared by dry mixing the fingolimod with at least one pharmaceutically acceptable excipient such as an MFC, a sugar alcohol, antioxidant, filler or mixtures thereof.
  • the dry mixture is then granulated with a suitable solvent such as water, an organic solvent such as C 1 -C 6 branched or straight chain alcohols, ethers, esters or ketones or mixtures.
  • the granulating liquid comprising the suitable solvent may also comprise one or more pharmaceutical excipients such as binders, solubilizing agents, antioxidants, chelating agents and mixtures thereof.
  • the fingolimod granules may be dried, and sized if necessary. The dried and sized fingolimod granules can be blended with additional pharmaceutical excipients such as a lubricant and compressed into a tablet.
  • the solid dosage form of the present invention is prepared by first preparing a drug/MFC, preferably CAF sugar alcohol, liquid composition.
  • the drug/MFC liquid composition comprises the fingolimod or pharmaceutically acceptable salt thereof, at least one MFC which is preferably at least one CAF sugar alcohol, a pharmaceutically acceptable solvent, optionally at least one solubilizing agent and optionally at least one antioxidant.
  • the pharmaceutically acceptable solvent can be water, an organic solvent, or a combination thereof.
  • the organic solvent can be any organic solvent commonly used in the manufacture of pharmaceutical products such as alcohols, ethers, and esters. Some of the preferred organic solvents are acetone and C 1 to C 6 alcohols such as methanol, ethanol, propanol, isopropanol, butanol, and combinations therefore.
  • the fingolimod or pharmaceutically acceptable salt thereof may be dissolved or suspended in the drug/MFC liquid composition. It is preferred that the fingolimod or pharmaceutically acceptable salt thereof is dissolved in the drug/MFC liquid composition and the MFC comprise at least one CAF sugar alcohol.
  • the CAF sugar alcohol should be dissolved in the drug/CAF sugar alcohol liquid composition. It is believed that dissolving the CAF sugar alcohol in the pharmaceutically acceptable solvent of the drug/CAF sugar alcohol liquid composition will allow the CAF sugar alcohol to be converted into an amorphous form and thereby be present in the solid dosage form of the present invention in part or substantially in an amorphous form.
  • an NCF sugar alcohol may also be dissolved or suspended in the drug/MFC liquid composition.
  • Additional pharmaceutical excipients may also be dissolved or suspended in the drug/MFC liquid composition.
  • the drug/MFC liquid composition may be dried to create a drug/MFC matrix.
  • the drying step can be accomplished by spray drying, freeze drying vacuum drying, oven drying, or a combination thereof.
  • the drug/MFC liquid composition is dried using known conventional spray drying apparatus such as those described in U.S. Pat. No. 5,587,180 and Remington, The Science and Practice of Pharmacy , 22 n d ed. (2013), pp. 791-792 which are incorporated herein by reference.
  • the powder created by the spray drying of the drug/MFC liquid composition may be mixed with additional sugar alcohols such as NCF sugar alcohols and pharmaceutically acceptable excipients and further processed into a solid dosage form in accordance with the present invention. It is believed that the powder created by the spray drying step will contain a matrix comprising the fingolimod or pharmaceutically acceptable salt thereof and the MFC excipient. If the MFC excipient comprises at least one CAF sugar alcohol, the CAF sugar alcohol is present in the powder or matrix, either totally or substantially in part, in an amorphous form.
  • the drug/MFC liquid composition with or without the NCF sugar alcohol and additional pharmaceutical excipients such as a solubilizing agent and an antioxidant, may be spray dried by using a conventional fluid bed granulator as described generally by Remington, The Science and Practice of Pharmacy , 22 n d ed. (2013), pp. 956-957 which is incorporated herein by reference.
  • the substrate in the fluidized bed onto which the drug/MFC liquid composition is sprayed may be a sugar alcohol, one of the pharmaceutically acceptable excipients previously described or a combination thereof.
  • the substrate in the fluidized bed comprises all or part of the NCF sugar alcohol that is present in the solid dosage form.
  • the coated substrate created by this spray drying of the drug/MFC liquid composition may be mixed with additional sugar alcohols such as NCF sugar alcohols and pharmaceutically acceptable excipients and further processed into a solid dosage form in accordance with the present invention. It is believed that the coating on the substrate will contain a matrix comprising the fingolimod or pharmaceutically acceptable salt thereof and the MFC excipient. If the MFC excipient comprises at least one CAF sugar alcohol, the CAF sugar alcohol may be present in the matrix, either totally or substantially in part, in an amorphous form. If a solubilizing agent is present in the liquid composition, the coating may also comprise, in whole in in part, a salt, conjugate, complex or co-precipitate of the fingolimod and solubilizing agent.
  • the fingolimod may be dissolved, suspended or disbursed in a suitable solvent along with additional pharmaceutical excipients such as a sugar alcohol, a solubilizing agent and an antioxidant and the resulting fingolimod solution, suspension or dispersion may be freeze dried using conventional freeze drying or lyophilization equipment and processes such as those described in U.S. Pat. Nos. 4,371,516 and 4,767,789, and Remington, The Science and Practice of Pharmacy , 22 n d ed. (2013), pp. 891-894 which are incorporated herein by reference.
  • the fingolimod solution, suspension or dispersion may be filled into preformed molds which are then lyophilized, creating the solid dosage forms of the present invention in situ, and the molds may be sealed and packaged for distribution.
  • the solid dosage form is to be prepared in situ by this method, it is preferred that at least one sugar alcohol, such as a CAF and/or NCF sugar alcohol and any additional pharmaceutically acceptable excipients such as a binder will included in the fingolimod solution, suspension or dispersion prior to freeze drying or lyophilization.
  • the resulting in situ formed solid dosage forms will contain a matrix comprising the fingolimod or pharmaceutically acceptable salt, conjugate or complex thereof and the CAF sugar alcohol wherein the CAF sugar alcohol is present, either totally or substantially in part, in an amorphous form.
  • the freeze dried composition may be further processed by seizing and/or mixing the freeze dried composition with additional pharmaceutically acceptable excipients such as NCF sugar alcohols and lubricants and further processed into a solid dosage form in accordance with the present invention.
  • the resulting mixture will contain the freeze dried particles that comprise a matrix comprising the fingolimod or pharmaceutically acceptable salt, conjugate, or complex thereof and the CAF sugar alcohol wherein the CAF sugar alcohol is present, either totally or substantially in part, in an amorphous form. It is also believed that the fingolimod and solubilizing agent if included in the liquid composition will be present in the solid matrix, in whole or in part, as a salt, conjugate or complex of the fingolimod and solubilizing agent.
  • the fingolimod may be dissolved, suspended or disbursed in a suitable solvent, with or without additional pharmaceutical excipients such as a CAF sugar alcohol, a NCF sugar alcohol, a solubilizing agent and an antioxidant, and the resulting fingolimod solution, suspension or dispersion may be vacuum dried using equipment and processes such as those described in U.S. Pat. No. 5,298,261 which is incorporated herein by reference.
  • the fingolimod solution, suspension or dispersion may be filled into preformed molds which are then vacuum dried, creating the solid dosage forms of the present invention in situ, and the molds may be sealed and packaged for distribution.
  • the sugar alcohol and any additional pharmaceutically acceptable excipients such as a binder should be present in the fingolimod solution, suspension or dispersion. It is believed that in situ formed solid dosage form prepared in the embodiment which also contain a CAF sugar alcohol in the fingolimod solution, suspension or dispersion will produce a matrix comprising the fingolimod or pharmaceutically acceptable salt thereof and the CAF sugar alcohol wherein the CAF sugar alcohol is present, either totally or substantially in part, in an amorphous form.
  • the vacuum dried composition may be further processed by seizing and/or mixing the vacuum dried composition with additional pharmaceutically acceptable excipients such as NCF sugar alcohols and lubricants and further processed into a solid dosage form in accordance with the present invention.
  • additional pharmaceutically acceptable excipients such as NCF sugar alcohols and lubricants
  • the resulting mixture will contain the vacuum dried particles that comprise a matrix comprising the fingolimod or pharmaceutically acceptable salt thereof and the CAF sugar alcohol wherein the CAF sugar alcohol is present, either totally or substantially in part, in an amorphous form.
  • the fingolimod and solubilizing agent if included in the liquid composition may be present in the solid matrix, in whole or in part, as a salt, conjugate or complex of fingolmod and solubilizing agent.
  • the fingolimod matrix resulting from the drying steps of the forgoing embodiments may be combined with additional pharmaceutically acceptable excipients and formed into a tablet, granule, or pellet for administration to a patient.
  • a cyclodextrin is employed in the present invention, it should be incorporated into the fingolimod solutions, suspensions or dispersions described above prior to the application of the fingolimod solution, suspension or dispersion onto the substrate.
  • the order in which the cyclodextrin and fingolimod are added to the solution, suspension or dispersion along with any additional desired excipients such as a MFC, binder or antioxidant are not critical, however the fingolimod solution, suspension or dispersion comprising the cyclodextrin should be stirred for a sufficient time to allow the fingolimod to complex with the cyclodextrin.
  • an anionic surfactant is employed in the present invention, it should be incorporated into the fingolimod solutions, suspensions or dispersion described above prior to the application of the fingolimod solution, suspension or dispersion onto the substrate.
  • the order in which the anionic surfactant and fingolimod are added to the solution, suspension or dispersion along with any additional desired excipients such as a MFC, binder or antioxidant are not critical, however the fingolimod solution, suspension or dispersion comprising the anionic surfactant should be stirred for a sufficient time to allow the fingolimod to react with the anionic surfactant if such as reaction is desired.
  • the solid dosage form of the present invention may also be prepared by dry blending the fingolimod with at least one sugar alcohol and at least one additional pharmaceutical excipient such as a lubricant and optionally an antioxidant and compressing the dry blend directly into a tablet.
  • the fingolimod may be dry blended with at least one sugar alcohol and at least one additional pharmaceutical excipient and compressed using a roller compressor or tablet die.
  • the resulting compressed material will be milled or ground to create fingolimod aggregates that may be further processed, such as blended with a lubricant, before being formed into the final dosage form, i.e., tablet, pellet or granule.
  • the method of this embodiment of the invention provides for a two-step treatment, which includes a humidification step and a drying step. Both treatments can be carried out in a single environmental chamber where both temperature and humidity can be accurately controlled. Many means to effect these steps are available and the invention is not limited by the use of any particular apparatus.
  • the treatment condition of the humidification step should be set at a lower temperature and a higher moisture level (higher relative humidity) than the drying step.
  • the desired final product properties can be achieved by routine testing and optimization of treatment conditions that are dependent on individual formulations.
  • water is absorbed into the tablet, granule or pellet.
  • a water-soluble polymer binder which may also function as an MFC
  • the binder, as well as the tablet, granule or pellet swells upon absorption of the water, allowing more thorough wetting (hydration) of the other components of the formulation and deeper penetration of the wetting agent (water) into the tablet interior.
  • the water is removed from the tablet, granule or pellet. This loss of water in the drying process results in a harder tablet.
  • the relative humidity (RH) in the humidification step is between about 50% and 100%, preferably between about 60% and about 85% and most preferably about 65% to about 80%; the humidification step lasts for between about 5 minutes to about 12 hours, preferably about 15 minutes to about 6 hours, and most preferably about 30 minutes to about 3 hours; and the temperature at which the humidification step is carried out can be between about 20° C. to about 50° C., preferably about 25° C. to about 45° C.
  • Different drying conditions can be used to achieve the desired dosage form hardness, which is measured after the dosage form is dried.
  • This drying step is typically conducted in an oven at a temperature between 30° C. and 75° C.
  • the temperature should be set below the melting point of the components in the tablet, granule, or pellet but higher than room temperature.
  • the time for the drying can vary depending upon the dosage form and drying conditions.
  • the dosage from should be dried until it has a moisture content of less than 5%, preferably less than 4%, and most preferably less than 3% as determined by standard pharmaceutical measurements such as Karl Fisher.
  • the solid dosage form prepared in accordance with the present invention is a tablet, granule, or pellet, it should exhibit a hardness in the range of about 5 newtons (N) to about 350.0 N, preferably about 10 N to about 250 N, and most preferably about 15 N to about 150 N.
  • the solid dosage form prepared in accordance with the present invention is a tablet, granule, or pellet, especially the solid dosage form that was subjected to humidification and drying, it should exhibit a friability of less than 2%, preferably less than 1.5%, and most preferably less than 1.0%.
  • Embodiments of the solid dosage forms of the present invention may dissolve in a patient’s oral cavity in less than 2.5 minutes, preferably less than 2.0 minutes, and most preferably less than 1.5 minutes.
  • Embodiments of the solid dosage forms of the present invention may disintegrate when tested using a USP Disintegration apparatus and method in less than 2.5 minutes, preferably less than 2.0 minutes, and most preferably less than 1.5 minutes.
  • the solid dosage forms of the present invention should be stable. More specifically, the solid dosage forms of the present invention will contain about 2.0% or less of any individual fingolimod degradation product, preferably about 1.5% or less of any individual fingolimod degradation product, and most preferably about 1.0% or less of any individual fingolimod degradation product when the solid dosage form is stored in a sealed bottle, preferably a sealed plastic bottle such as a high density polyethylene bottle (with or without a desiccant) or a sealed aluminum foil pouch (with or without a desiccant), at approximately 25° C. and approximately 60% relative humidity for at least three months, preferably at least six months and most preferably at least one year and/or at approximately 40° C. and approximately 75% relative humidity for one month, two months, or three months.
  • a sealed plastic bottle such as a high density polyethylene bottle (with or without a desiccant) or a sealed aluminum foil pouch (with or without a desiccant)
  • the solid dosage forms of the present invention should also contain a total amount of fingolimod degradation products of about 2.5% or less, preferably about 2.0% or less, and most preferably about 1.5% or less when the solid dosage form is stored in a sealed bottle, preferably a sealed plastic bottle such as a high density polyethylene bottle (with or without a desiccant) or a sealed aluminum foil pouch (with or without a desiccant), stored at approximately 25° C. and approximately 60% relative humidity for at least three months, preferably at least six months, and most preferably at least one year and/or at approximately 40° C. and approximately 75% relative humidity for one month, two months, or three months.
  • a sealed plastic bottle such as a high density polyethylene bottle (with or without a desiccant) or a sealed aluminum foil pouch (with or without a desiccant)
  • stored at approximately 25° C. and approximately 60% relative humidity for at least three months preferably at least six months, and most preferably at least one year and/or at approximately 40° C. and approximately
  • the solid oral dosage forms of the present invention should exhibit a pharmacokinetic profile that is bioequivalent to the commercially available GILENYA® capsule product.
  • bioequivalent is used in accordance with the United States Food and Drug Administration’s (“FDA”) definition.
  • FDA United States Food and Drug Administration
  • the FDA recommends in its August 2011 Draft Guidance on Fingolimod to conduct two pharmacokinetic studies to establish bioequivalence to the commercially available GILENYA® capsule product.
  • the first study is a single-dose, two-way cross over study wherein three (3) 0.5 mg GILENYA® capsules for a total dose of 1.5 mg of fingolimod and a similar 1.5 mg dose of the test product are administered to healthy male and non-pregnant females under fasting conditions.
  • the second study is similar to the first study except the dosing is conducted under fed (non-fasting) conditions.
  • the solid oral dosage forms of the present invention would be considered bioequivalent to the commercially available GILENYA® capsule product if the log transformed ratio of the C max and AUC for the solid oral dosage form of the present invention (test product) compared to the GILENYA® capsule(s) (reference product) are shown to be within 80-125%, using the 90% confidence interval.
  • the log transformed ratio of the C max and AUC may be obtained from a single does or multiple dose randomized cross over study under fed, fasted or both fed and fasted conditions.
  • the subjects should exhibit a time to maximum fingolimod concentration (T max ) of about 8 to about 40 hours, preferably about 10 to about 35 hours and most preferably about 12 to about 30 hours, a dose adjusted maximum fingolimod concentration (C max/dose ) of about 0.50 ng/ml/mg to about 2.0 ng/ml/mg, preferably about 0.55 ng/ml/mg to about 1.50 ng/ml/mg, and most preferably about 0.60 ng/ml/mg to about 1.25 ng/ml/mg and a dose adjusted area under the plasma concentration-time curve (AUC 0- ⁇ /dose ) of about 100 ng ⁇ hr/ml/mg to about 300 ng-hr/ml/mg, preferably about 125 ng ⁇ hr/ml/mg to about 275
  • Another embodiment of the present invention is a fingolimod salt, conjugate or complex formed by reacting fingolimod with an anionic C 10 -C 30 carboxylic acid, an anionic C 10 -C 30 alcohol, an anionic sulfate, an anionic sulfite or mixture thereof and solid dosage forms containing the fingolimod salt, conjugate or complex formed by reacting fingolimod with an anionic C 10 -C 30 carboxylic acid, an anionic C 10 -C 30 alcohol, an anionic sulfate, an anionic sulfite or mixture thereof.
  • the fingolimod/anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite salt, conjugate or complex may be formed by dissolving a fingolimod salt such as fingolimod HCl in a suitable solvent such as water, an organic solvent such as C 1 -C 6 branched or straight chain alcohols, ethers, esters or ketones or mixtures thereof, adding an anionic C 10 -C 30 carboxylic acid, an anionic C 10 -C 30 alcohol, an anionic sulfate, an anionic sulfite or mixture thereof to the fingolimod solution and mixing the resulting reaction mass.
  • a fingolimod salt such as fingolimod HCl
  • a suitable solvent such as water, an organic solvent such as C 1 -C 6 branched or straight chain alcohols, ethers, esters or ketones or mixtures thereof
  • anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite or mixture thereof may be dissolved in a suitable solvent, adding the fingolimod HCl added to the anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite or mixture thereof solution and mixing the resulting reaction mass.
  • the fingolimod/anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite salt, conjugate or complex may also be formed by dissolving fingolimod HCl in a suitable solvent, dissolving the anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite or mixture thereof in a suitable solvent, combing the fingolimod solution and the anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, an anionic sulfate, anionic sulfite or mixture thereof solution and mixing the resulting reaction mass.
  • the solvent is removed from the resulting reaction mass by conventional techniques such as evaporation or filtration to isolate the fingolimod/anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite or mixture thereof salt, conjugate or complex.
  • the isolated fingolimod/anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite or mixture thereof salt, conjugate or complex may be used in the solid dosage forms of the present invention.
  • the isolated fingolimod/anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite or mixture thereof salt, conjugate or complex may also be used in the solid dosage forms that do not contain a sugar alcohol.
  • the molar ratio of anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite compound(s) to fingolimod in the reaction mass should range from about 0.5 moles of anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite compound(s) to about 3 moles of anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite compound(s) for each mole of fingolimod present in the reaction mass, preferably about 0.75 moles of anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite compound(s) to about 2 moles of anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic
  • the anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite or mixture thereof employed in the reaction mass is an anionic sulfate or anionic sulfite compound such as sodium metabisulfate or an anionic organosulfate or anionic oragansulfite compound such as an anionic C 10 -C 30 carboxylic acid sulfate or an anionic C 10 -C 30 alcohol sulfate or combinations thereof.
  • anionic C 10 -C 30 carboxylic acid examples include but are not limited to sodium lauryl sulfate, sodium oleate, or sodium tetradecyl sulfate.
  • the fingolimod/anionic C 10 -C 30 carboxylic acid, anionic C 10 -C 30 alcohol, anionic sulfate, anionic sulfite salt, conjugate or complex may also be formed during or as part of the manufacturing of the solid dosage forms of the present invention.
  • a stable orally disintegrating tablet which is bioequivalent to the 0.5 mg GILENYA® capsule comprising:
  • a stable orally disintegrating tablet which is bioequivalent to the 0.5 mg GILENYA® capsule comprising:
  • the present invention provides an orally disintegrating tablet comprising:
  • the present invention provides an orally disintegrating tablet comprising:
  • a method of treatment of multiple sclerosis in patients in need of such treatment which comprises administering an effective amount of fingolimod or any pharmaceutically acceptable form thereof in the form of the compositions or tablets as described herein.
  • compositions or tablets described herein for use in the treatment of multiple sclerosis are also provided.
  • compositions or tablets described herein for the manufacture of a medicament for the treatment of multiple sclerosis.
  • a medicament for the treatment of multiple sclerosis comprising the compositions or tablets as described herein.
  • MS multiple sclerosis
  • RRMS relapsing-remitting MS
  • CPMS chronic progressive MS
  • PPMS primary progressive MS
  • PRMS progressive relapsing MS
  • SPMS secondary progressive MS
  • test methods referred to herein are to be conducted in accordance to the general chapters of the United States Pharmacopeia (USP) 38 (2015) which are incorporated herein by reference:
  • a rapidly disintegrating fingolimod tablet can be prepared by dissolving fingolimod in an aqueous solution of lactitol. The solution is sprayed onto mannitol and then dried. The resulting product is sifted and blended with other excipients before being compressed into tablets.
  • the tablets should have the following composition:
  • Fingolimod HCl 0.56 mg* Lactitol 20 mg Mannitol 177.44 mg Magnesium Stearate 2 mg *equivalent to 0.5 mg fingolimod
  • the tablets are placed in a humidity chamber and exposed to 85% relative humidity at 25° C. - 30° C. for about 6 hours. After humidification, the tablets are dried at approximately 40° C. - 45° C. at 30% relative humidity for about 6 hours.
  • a rapidly disintegrating fingolimod tablet can be prepared by dissolving fingolimod in an aqueous solution of lactitol and mannitol. The solution is sprayed-dried to yield a solid powder. The resulting product is blended with a lubricant and compressed into tablets.
  • the tablets should have the following composition:
  • Fingolimod HCl 0.56 mg* Lactitol 20 mg Mannitol 177.44 mg Magnesium Stearate 2 mg *equivalent to 0.5 mg fingolimod
  • the tablets are placed in a humidity chamber and exposed to 85% relative humidity at 25° C. - 30° C. for about 6 hours. After humidification, the tablets are dried at approximately 40° C. - 45° C. at 30% relative humidity for about 6 hours.
  • the humidified and dried tablets should exhibit a hardness of greater than 2.5 kilopounds, a friability of less than 2% and should disintegrate in less than 60 seconds when placed in a USP disintegration apparatus.
  • a rapidly disintegrating fingolimod tablet can be prepared by lyophilization an aqueous solution of gelatin, lactitol, and mannitol. The solution is transferred to thermoformed blister trays and freeze dried to form tablets.
  • the tablets should have the following composition:
  • the blister trays are freeze-dried at a shelf temperature of -45° C.
  • the resulting product is then heat-dried at a shelf temperature of between 50° C. - 55° C. for four hours.
  • a rapidly disintegrating fingolimod tablet can be prepared by the method described in Example 1 wherein the tablet has the following composition:
  • a rapidly disintegrating fingolimod tablet can be prepared by the method described in Example 2 wherein the tablet has the following composition:
  • a rapidly disintegrating fingolimod tablet can be prepared by the method described in Example 3 wherein the tablet has the following composition:
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • the above tablets were prepared by dissolving the sodium lauryl sulfate in water. Fingolimod HC1, povidone and lactitol were subsequently added while stirring to create a granulating solution.
  • the mannitol was added to a top spray fluidized bed granulator.
  • the granulating solution was sprayed onto the mannitol.
  • the resulting drug layered mannitol granules were dried and sized, then blended with either the sodium stearyl fumarate or magnesium stearate, and compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • the above tablets were prepared by dissolving the hydroxypropyl- ⁇ -cyclodextrin in water. Fingolimod HC1, povidone and lactitol were subsequently added while stirring to create a granulating solution.
  • the mannitol was added to a top spray fluidized bed granulator.
  • the granulating solution was sprayed onto the mannitol.
  • the resulting drug layered mannitol granules were dried and sized, then blended with either the sodium stearyl fumarate or magnesium stearate, and compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • the above tablets were prepared by dissolving the hydroxypropyl methylcellulose E5LV in water. Fingolimod HC1, povidone and lactitol were subsequently added while stirring to create a granulating solution.
  • the mannitol was added to a top spray fluidized bed granulator.
  • the granulating solution was sprayed onto the mannitol.
  • the resulting drug layered mannitol granules were dried and sized, then blended with either the sodium stearyl fumarate or magnesium stearate, and compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • the above tablets were prepared by dissolving the lactitol and povidone in water. Fingolimod HC1 was subsequently added while stirring to create a granulating solution.
  • the mannitol was added to a top spray fluidized bed granulator.
  • the granulating solution was sprayed onto the mannitol.
  • the resulting drug layered mannitol granules were dried and sized, then blended with either the sodium stearyl fumarate or magnesium stearate, and compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • the above tablets were prepared by dissolving the hydroxypropyl- ⁇ -cyclodextrin in water. Fingolimod HC1, povidone and lactitol were subsequently added while stirring to create a granulating solution.
  • the mannitol was added to a top spray fluidized bed granulator.
  • the granulating solution was sprayed onto the mannitol.
  • the resulting drug layered mannitol granules were dried and sized, then blended with either the sodium stearyl fumarate or magnesium stearate, and compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • Example 10 The tablets were tested according to the procedures outlined in Example 10 and exhibited the following properties:
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • the above tablets were prepared by dry blending the mannitol, fingolimod HC1 and sodium metabisulfate using a geometric technique to form an ordered dry mixture.
  • the ordered dry mixture was added to a top spray fluidized bed granulator and granulated with an aqueous solution of povidone and lactitol.
  • the resulting drug granules were dried and sized, then blended with either the sodium stearyl fumarate or magnesium stearate, and compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • the above tablets were prepared by dry blending the mannitol, fingolimod HC1 and butylated hydroxytoluene using a geometric technique to form an ordered dry mixture.
  • the ordered dry mixture was added to a top spray fluidized bed granulator and granulated with an aqueous solution of povidone and lactitol.
  • the resulting drug granules were dried and sized, then blended with either the sodium stearyl fumarate or magnesium stearate, and compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • Example 10 The tablets were tested according to the procedures outlined in Example 10 and exhibited the following properties:
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • Tablets 14A were prepared by dry blending the mannitol, fingolimod HC1, butylated hydroxytoluene and disodium EDTA using a geometric technique to form an ordered dry mixture.
  • the ordered dry mixture was added to a top spray fluidized bed granulator and granulated with an aqueous solution of povidone and lactitol.
  • the resulting drug granules were dried and sized, then blended with magnesium stearate, and compressed into 9 mm round tablets.
  • Tablets 14B were prepared by dry blending the mannitol, fingolimod HC1 and butylated hydroxytoluene using a geometric technique to form an ordered dry mixture.
  • the ordered dry mixture was added to a top spray fluidized bed granulator and granulated with an aqueous solution of povidone and lactitol.
  • the resulting drug granules were dried and sized.
  • the disodium EDTA was dissolved in water and mixed with magnesium stearate to form magnesium stearate granules.
  • the magnesium stearate granules were dried at 105° C. for ten minutes, cooled then blended, and the dried and sized drug granules were compressed into 9 mm round tablets
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • Rapidly disintegrating fingolimod tablets prepared in Examples 7-14 were packaged in aluminum foil pouch and heat sealed. The sealed pouches were stored at 60° C. and 60% relative humidity. After 14 days the tablets were tested using a validated HPLC methodology and impurity were reported as follows:
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • the above tablets were prepared by dissolving 75 g of hydroxypropyl- ⁇ -cyclodextrin in 300 g of purified water. 4.2 g of fingolimod HCl, 30 g of povidone and 45 g of lactitol were subsequently added to the cyclodextrin aqueous solution while stirring to create a granulating solution.
  • 1,341 g of mannitol was added to a top spray fluidized bed granulator.
  • the granulating solution was sprayed onto the mannitol.
  • the resulting drug layered mannitol granules were dried and sized, then blended with 5 g of magnesium stearate, and compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 0.5 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • the humidified and dried tablets were packaged in aluminum blister card and stored at 60° C. and 60% relative humidity. After 14 days the tablets were tested using an HPLC methodology and the impurity profile was reported as follows:
  • the humidified and dried tablets packaged in aluminum blister card were also stored at 40° C. and 75% relative humidity. After one month the tablets were tested using an HPLC methodology and the impurity profile was reported as follows:
  • Rapidly disintegrating fingolimod tablets with the following composition were prepared:
  • Granulation Solution B Purified Water N/A* Lactitol Monohydrate 3.00 (1.50) Povidone (Plasdone K29/32) 2.00 (1.00) Mannitol (Pearlitol 160C) 93.00 (46.50) Granulation 2 Granulation Solution C Purified Water N/A* Lactitol Monohydrate 3.00 (1.50) Povidone (Plasdone K29/32) 2.00 (1.00) Mannitol (Pearlitol 160C) 94.70 (47.35) Blend Magnesium Stearate 0.60 (0.30)
  • Granulation 1 was prepared by:
  • Granulation 2 was prepared by:
  • Granulation 1 and Granulation 2 were combined and blended with 9 g of magnesium stearate and resulting blend was compressed into 9 mm round tablets.
  • the tablets were placed in a humidity chamber and exposed to 75% relative humidity at 30° C. for about 1 hours. After humidification, the tablets were dried at approximately 30° C. at 30% relative humidity for about 2 hours.
  • the humidified and dried tablets were packaged in aluminum blister card and stored at 60° C. and 60% relative humidity. After 14 days the tablets were tested using an HPLC methodology and the impurity profile was reported as follows:
  • the tablets from Examples 16 and 17 were administered to healthy adult male and non-pregnant human volunteer subjects, in a single-center, single-dose, randomized, three treatment, parallel study. Twenty-four subjects completed the study. Each subject received a single dose of the following treatments under fasted conditions:
  • Treatment 1 8 subjects were administered three (3) tablets of Example 16 wherein the first of the three tablets was placed on the subject’s tongue. The subject was instructed to allow the first tablet to remain in the oral cavity for 30 seconds, then drink 50 mL of water. This procedure was repeated sequentially for the second and third tablets so all three tablets were administered in about 2 minutes or less;
  • Treatment 2 8 subjects were administered three (3) tablets of Example 17 wherein the first of the three tablets was placed on the subject’s tongue. The subject was instructed to allow the first tablet to remain in the oral cavity for 30 seconds, then drink 50 mL of water. This procedure was repeated sequentially for the second and third tablets so all three tablets were administered in about 2 minutes or less;
  • Treatment 3 8 subjects were administered three (3) commercially available 0.5 mg GILENYA® capsules with 200 mL of water.
  • Treatment 1 (Test Product 1- Example 16) AUC 0-t (ng*h/mL) AUC 0- ⁇ (ng*h/mL) C max (ng/mL) T max (h) MRT (h) T 1 ⁇ 2 (h) RSQ subject 103 152.6 360.5 1.734 36.00 203.85 132.19 0.8385 106 105.1 162.2 1.368 30.00 113.79 97.14 0.9957 111 140.3 409.2 1.567 48.00 273.44 184.15 0.6093 114 151.7 305.5 1.932 12.00 165.05 105.72 0.8683 116 128.4 235.2 1.432 16.00 150.07 98.29 0.9838 117 102.5 197.4 1.385 30.00 158.19 102.89 0.8533 123 96.6 148.4 1.209 30.00 112.17 65.68 0.9999 126 140.1 229.3 1.612 30.00 123.69 74.93 0.9995 Mean 127.2 255.9 1.530 2
  • Treatment 2 Treatment 2 (Test Product 2- Example 17) AUC 0-t (ng*h/mL) AUC 0- ⁇ (ng*h/mL) C max (ng/mL) T max (h) MRT (h) T 1 ⁇ 2 (h) RSQ subject 104 116.0 254.6 1.304 36.00 191.49 126.83 0.9313 107 120.7 235.1 1.355 30.00 163.42 107.51 0.8293 110 128.4 242.4 1.633 12.00 157.42 105.58 0.9268 113 169.7 428.2 1.828 14.00 224.82 148.29 0.8844 118 106.3 331.5 1.076 30.00 281.42 184.04 0.7840 119 119.3 224.0 1.571 12.00 160.97 112.50 0.7897 121 82.7 170.5 0.973 30.00 177.95 118.02 0.9034 124 144.5 655.4 1.574 6.00 474.73 327.21 0.622 Mean 123.5 317.7 1.414 21.25
  • Treatment 3 (Reference Product) AUC 0-t (ng*h/mL) AUC 0- ⁇ (ng*h/mL) C max (ng/mL) T max (h) MRT (h) T 1 ⁇ 2 (h) RSQ subject 101 141.0 284.7 1.714 30.00 174.66 118.98 0.9825 102 151.7 323.5 2.015 14.00 170.23 103.65 0.5470 105 127.5 433.1 1.495 36.00 335.49 229.44 0.8827 108 111.1 193.1 1.449 30.00 136.37 88.30 0.9102 112 133.9 223.4 1.628 12.00 128.51 80.96 0.9858 115 111.9 252.8 1.281 30.00 193.22 125.18 0.8816 120 101.7 222.7 1.513 20.00 192.44 130.05 0.9111 122 123.7 616.5 1.501 30.00 541.99 376.49 0.9633 Mean 125.3 318.7 1.575 25.25 234.11 156.63 0.8830 SD 16.8 142.1
  • the tablets from Examples 16 and 17 were administered to healthy adult male and non-pregnant human volunteer subjects, in a single-center, single-dose, randomized, three treatment, parallel study. Twenty-four subjects were enrolled. Each subject received a single dose of the following treatments under fed conditions:
  • Treatment 1 8 subjects were administered three (3) tablets of Example 16 wherein the first of the three tablets was placed on the subject’s tongue. The subject was instructed to allow the first tablet to remain in the oral cavity for 30 seconds, then drink 50 mL of water. This procedure was repeated sequentially for the second and third tablets so all three tablets were administered in about 2 minutes or less;
  • Treatment 2 7 subjects were administered three (3) tablets of Example 17 wherein the first of the three tablets was placed on the subject’s tongue. The subject was instructed to allow the first tablet to remain in the oral cavity for 30 seconds, then drink 50 mL of water. This procedure was repeated sequentially for the second and third tablets so all three tablets were administered in about 2 minutes or less;
  • Treatment 3 9 subjects were administered three (3) commercially available 0.5 mg GILENYA® capsules with 200 mL of water.
  • Treatment 1 (Test Product 1- Example 16) AUC 0-t (ng*h/mL) AUC 0- ⁇ (ng*h/mL) C max (ng/mL) T max (h) MRT (h) T 1 ⁇ 2 (h) RSQ subject 101 154.5 347.0 1.723 30.00 193.25 125.72 0.9549 106 125.5 223.8 1.494 30.00 147.97 102.01 0.9237 110 132.9 294.2 1.411 16.00 190.10 124.10 0.9690 112 140.5 234.2 1.889 30.00 129.35 85.09 0.9762 113 146.8 280.0 1.670 8.00 152.03 94.10 0.9533 115 88.7 148.0 1.075 30.00 117.72 60.75 0.8783 120 167.8 361.8 2.109 30.00 193.56 134.07 0.9746 121 121.0 297.0 1.410 30.00 202.63 125.46 0.7138 Mean 134.7 273.2 1.598 25.50 165.83 106
  • Treatment 2 Treatment 2 (Test Product 2- Example 17) AUC 0-t (ng*h/mL) AUC 0- ⁇ (ng*h/mL) C max (ng/mL) T max (h) MRT (h) T 1 ⁇ 2 (h) RSQ subject 102 116.6 181.0 1.286 36.00 113.71 69.84 0.9665 107 129.9 546.8 1.428 30.00 438.42 302.52 0.9511 109 140.3 231.0 1.752 30.00 126.49 80.28 0.9709 117 92.5 186.2 1.161 30.00 170.44 113.38 0.9904 118 127.8 234.8 1.492 36.00 148.75 98.43 0.9191 122 132.6 270.1 1.630 30.00 175.54 117.78 0.9852 123 142.9 259.5 1.591 30.00 146.18 91.64 0.8481 Mean 126.1 272.8 1.477 31.71 188.50 124.84 0.9473 SD 17.2 125.4 0.205 2.93 112.
  • Treatment 3 (Reference Product) AUC 0-t (ng*h/mL) AUC 0- ⁇ (ng*h/mL) C max (ng/mL) T max (h) MRT (h) T 1 ⁇ 2 (h) RSQ subject 103 134.7 211.9 1.507 30.00 117.55 71.42 0.9509 104 191.5 373.1 2.042 36.00 158.49 98.70 0.9903 105 131.0 334.8 1.482 30.00 233.16 155.72 0.9996 108 158.1 226.7 1.735 36.00 100.25 47.35 1.0000 111 134.4 201.3 1.416 36.00 105.87 52.60 1.0000 114 141.2 235.2 1.503 72.00 128.11 76.30 1.0000 119 135.3 340.6 1.662 30.00 209.01 129.63 1.0000 124 105.4 152.9 1.463 30.00 102.91 58.11 0.9958 125 139.2 289.4 1.640 30.00 171.41 107.68 0.9388 Mean 141.2 262.9
  • Rapidly disintegrating fingolimod tablets with the following composition can also be prepared by the method described in Example 17:
  • a sodium lauryl sulfate solution was prepared by dissolving 1.00 g of sodium lauryl sulfate in 20 mL of water.
  • a fingolimod HCl solution was prepared by dissolving 1.00 g of fingolimod HCl in 20 mL of water. Subsequently, the sodium lauryl sulfate solution was slowly added to the fingolimod HCl solution and the resulting solution was stirred for 30 minutes. It was observed that a white dispersion/precipitate was formed. The resulted suspension was filtered and washed with water to isolate the white solid. The white solid was dried in a vacuum oven at 35-38° C. for 5 hours.
  • the melting point of the white solid was 124-126° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US18/091,481 2015-01-20 2022-12-30 Stable solid fingolimod dosage forms Abandoned US20230149302A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18/091,481 US20230149302A1 (en) 2015-01-20 2022-12-30 Stable solid fingolimod dosage forms
US18/243,735 US20240050365A1 (en) 2015-01-20 2023-09-08 Stable solid fingolimod dosage forms
US18/919,763 US20250041213A1 (en) 2015-01-20 2024-10-18 Stable solid fingolimod dosage form

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562105603P 2015-01-20 2015-01-20
US201562216100P 2015-09-09 2015-09-09
PCT/US2016/013938 WO2016118515A1 (en) 2015-01-20 2016-01-19 Stable solid fingolimod dosage forms
US15/084,226 US9925138B2 (en) 2015-01-20 2016-03-29 Stable solid fingolimod dosage forms
US15/918,582 US10555902B2 (en) 2015-01-20 2018-03-12 Stable fingolimod dosage forms
US16/778,186 US10925829B2 (en) 2015-01-20 2020-01-31 Stable solid fingolimod dosage forms
US17/177,569 US20210169793A1 (en) 2015-01-20 2021-02-17 Stable solid fingolimod dosage forms
US18/091,481 US20230149302A1 (en) 2015-01-20 2022-12-30 Stable solid fingolimod dosage forms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/177,569 Continuation US20210169793A1 (en) 2015-01-20 2021-02-17 Stable solid fingolimod dosage forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/243,735 Continuation US20240050365A1 (en) 2015-01-20 2023-09-08 Stable solid fingolimod dosage forms

Publications (1)

Publication Number Publication Date
US20230149302A1 true US20230149302A1 (en) 2023-05-18

Family

ID=56417652

Family Applications (3)

Application Number Title Priority Date Filing Date
US18/091,481 Abandoned US20230149302A1 (en) 2015-01-20 2022-12-30 Stable solid fingolimod dosage forms
US18/243,735 Abandoned US20240050365A1 (en) 2015-01-20 2023-09-08 Stable solid fingolimod dosage forms
US18/919,763 Pending US20250041213A1 (en) 2015-01-20 2024-10-18 Stable solid fingolimod dosage form

Family Applications After (2)

Application Number Title Priority Date Filing Date
US18/243,735 Abandoned US20240050365A1 (en) 2015-01-20 2023-09-08 Stable solid fingolimod dosage forms
US18/919,763 Pending US20250041213A1 (en) 2015-01-20 2024-10-18 Stable solid fingolimod dosage form

Country Status (8)

Country Link
US (3) US20230149302A1 (enrdf_load_stackoverflow)
EP (1) EP3247341A4 (enrdf_load_stackoverflow)
JP (1) JP2018502168A (enrdf_load_stackoverflow)
CN (1) CN107530301A (enrdf_load_stackoverflow)
AU (1) AU2016209466A1 (enrdf_load_stackoverflow)
CA (1) CA2974375A1 (enrdf_load_stackoverflow)
TW (1) TW201642842A (enrdf_load_stackoverflow)
WO (1) WO2016118515A1 (enrdf_load_stackoverflow)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199382A1 (en) * 2013-01-11 2014-07-17 Cadila Healthcare Limited Stable pharmaceutical compositions of an s1p receptor agonist
US9925138B2 (en) * 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2319502A1 (en) * 2003-04-08 2011-05-11 Novartis AG Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
AU2007302296A1 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
KR101600098B1 (ko) * 2007-10-12 2016-03-04 노파르티스 아게 스핑고신 1 포스페이트 (ｓ1ｐ) 수용체 조절제를 포함하는 조성물
AU2009315735B2 (en) * 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
WO2011131368A2 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
JO3177B1 (ar) * 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199382A1 (en) * 2013-01-11 2014-07-17 Cadila Healthcare Limited Stable pharmaceutical compositions of an s1p receptor agonist
US9925138B2 (en) * 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US10925829B2 (en) * 2015-01-20 2021-02-23 Handa Neuroscience, Llc Stable solid fingolimod dosage forms

Also Published As

Publication number Publication date
CN107530301A (zh) 2018-01-02
US20240050365A1 (en) 2024-02-15
WO2016118515A1 (en) 2016-07-28
CA2974375A1 (en) 2016-07-28
US20250041213A1 (en) 2025-02-06
TW201642842A (zh) 2016-12-16
JP2018502168A (ja) 2018-01-25
EP3247341A1 (en) 2017-11-29
AU2016209466A1 (en) 2017-08-10
EP3247341A4 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
US10925829B2 (en) Stable solid fingolimod dosage forms
TWI635863B (zh) 帕博西里之固態劑型
EP2646003B1 (en) Rapidly dispersing granules, orally disintegrating tablets and methods
EP4461357A2 (en) Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP6396980B2 (ja) ベンダムスチンの固体投与剤
CN101801347A (zh) 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法
KR20080013847A (ko) 활성 약제학적 성분의 안정화 조성물 및 방법
US20250041213A1 (en) Stable solid fingolimod dosage form
US20110257159A1 (en) Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
US20180344648A1 (en) Clobazam tablet formulation and process for its preparation
US20250064798A1 (en) Vilazodone composition, pharmaceutical preparation thereof, preparation therefor, and use thereof
AU2016217658B2 (en) Method of producing a granulated composition
AU2012241189A1 (en) Fast Dissolving Solid Dosage Form
US20150250720A1 (en) Tablet containing composite with cyclodextrin
EP4302755B1 (en) Palbociclib formulation containing an amino acid
CN102802613A (zh) 布洛芬钠片剂和制备包含布洛芬钠的药物组合物的方法
AU2015264861C1 (en) Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
HK40063384A (en) Solid dosage forms of palbociclib
HK1213783B (zh) 布洛芬钠片剂和制备包含布洛芬钠的药物组合物的方法
HK1169309B (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
HK1169309A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION